The earnings were in line with consensus, but the revenue decline and widening loss underscore the pre-revenue stage. The key catalyst is the Varseta-M data update in January 2027, which will inform registrational strategy. Monitor for any early data disclosures or FDA interactions before that date.
Drugs in focus
CTMX drug pipeline →Varseta-M
▲ Bullish Named in this 8-K- Impact
- Phase
- Phase 1
- Time to market
- If the Phase 1 update supports the registrational study planned for H1 2027, a potential FDA approval would likely be several years away, assuming successful pivotal trial execution. The Fast Track designation could accelerate timelines, but the drug is still in Phase 1 development.
- Next catalyst
- None dated
What to watchThe next major catalyst is the Phase 1 monotherapy data update in mCRC expected in January 2027 (roughly 2 months away). Positive data could support the planned registrational study start in H1 2027 and drive significant upside given the stock trades near cash value. Disappointing efficacy or safety signals could delay the pivotal program and pressure the stock toward its 52-week low of $2.11.
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+5- T+0 · Nov 6 $2.19entry
- T+1 · 8d ago −9.59%α −11.96% · $1.98
- T+5 · 4d ago −6.85%α −9.44% · $2.04
- T+6 · todayOpen
- T+20 · in 20d Pending
- T+60 · in 3mo Pending
Price Chart
How similar events traded
Executive Summary
Revenue decline reflects completion of the Astellas collaboration performance obligation. The company highlighted FDA Fast Track designation for Varseta-M and plans for a Phase 1 data update in January 2027, but the financial results show a pre-revenue clinical-stage biotech burning cash with no near-term product revenue.
Key Financial Metrics
Key Facts
- Q3 2026 revenue $1.7M vs $6.0M YoY, down 72%
- Net loss $(20.0M) vs $(14.2M) loss YoY
- Cash and investments $348.0M, runway into 2H 2028
- FDA Fast Track designation for Varseta-M in relapsed/refractory mCRC granted in August 2026
- Phase 1 monotherapy data update for Varseta-M expected January 2027
- Phase 1 expansion cohorts initiated in gastric/GEJ, PDAC, and BTC
Financial Impact
Revenue fell 72% YoY to $1.7M; operating loss widened to $(23.5M) from $(15.8M); cash burn continues with $348M in cash
Risk Factors
- No approved products; entirely dependent on clinical success of Varseta-M and CX-801
- Revenue decline reflects completion of collaboration agreements, no new revenue sources near term
- Cash runway to 2H 2028 assumes no unexpected cost overruns or delays
- Clinical trial risks: Varseta-M data may not support registrational study
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-449787 |
| Document: ctmx-20261105.htm | 0001193125-26-449787 |
| Document: 0001193125-26-449787-index-headers.html | 0001193125-26-449787 |
| Document: 0001193125-26-449787-index.html | 0001193125-26-449787 |
| Document: 0001193125-26-449787.txt | 0001193125-26-449787 |
| 8-K Data (Synthetic) | 0001193125-26-449787 |
Track record
10 reports on CTMX
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 10, 20266d ago SC 13G Neutral 2/10 Entry $1.98 Now $1.99 +0.25% settles Feb 8
- Nov 5, 202611d ago Press Release Bearish 5/10 No price data
- Nov 5, 202611d ago 8-K Neutral 4/10 Viewing Entry $2.19 Now $1.99 −9.36% settles Feb 4
- Oct 28, 202619d ago SC 13G/A Neutral 2/10 Entry $2.36 Now $1.99 −15.89% settles Jan 26
- Sep 22, 20267w ago Institutional Cluster Mixed 3/10 Entry $2.94 Now $1.99 −32.48% settles Dec 16
- Jun 22, 202621w ago 8-K Neutral 3/10 Entry $3.15 to $2.77 Now $1.99 −36.98% ▼ −12.22% −15.47% vs SPY
- Mar 17, 202634w ago Press Release Neutral 6/10 Entry $4.40 to $2.98 Now $1.99 −54.89% ▼ −32.27% −43.80% vs SPY
- Mar 16, 202635w ago Press Release Bearish 7/10 Entry $5.45 to $2.98 Now $1.99 +63.58% ▲ +45.32% +55.18% vs SPY
- Mar 16, 202635w ago Press Release Mixed 6/10 Entry $6.75 to $2.94 Now $1.99 −70.59% ▼ −56.44% −66.93% vs SPY
- Mar 4, 202636w ago Press Release Neutral 3/10 Entry $5.07 to $3.71 Now $1.99 −60.85% ▼ −26.82% −36.91% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers